Format

Send to

Choose Destination
See comment in PubMed Commons below
Indian J Gastroenterol. 1994 Jan;13(1):7-8.

A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen.

Author information

1
Dr Balabhai Nanavati Hospital and Research Center, Juhu, Bombay.

Abstract

BACKGROUND:

There have been conflicting data in literature about the value of Phyllanthus amarus in treating hepatitis B virus-related disorders.

AIM:

To evaluate the role of Phyllanthus amarus in eradication of the virus in hepatitis B carriers.

METHODS:

Phyllanthus amarus was administered to 30 asymptomatic carriers of hepatitis B surface antigen (HBsAg) in a dosage of 250 to 500 mg thrice daily for 4 to 8 weeks.

RESULTS:

None of the 30 subjects cleared HBsAg. Phyllanthus amarus was well tolerated, with no clinical side effects or changes in the organ profiles for safety evaluation.

CONCLUSION:

Phyllanthus amarus is not effective in clearing HBsAg in asymptomatic carriers of the antigen.

PMID:
8119752
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center